Dr. Reddy’s Launches Novel Acid Blocker Tegoprazan in India

Dr. Reddy’s Laboratories Ltd. said it has launched Tegoprazan, a next-generation potassium-competitive acid blocker for treating acid-related gastrointestinal diseases, under the brand name “PCAB” in India. The launch is part of its 2022 partnership with South Korea’s HK inno.N Corp.

Tegoprazan is indicated for conditions like erosive and non-erosive gastroesophageal reflux disease and gastric ulcers. In a multinational trial led by Dr. Reddy’s, 99% of erosive reflux patients achieved endoscopic healing by week eight.

The molecule is already approved in 21 countries, including China and South Korea, and has cleared phase-III trials in the US.